Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D498/04—Ortho-condensed systems

Definitions

• This invention relates to novel processes for the preparation of salts of clavulanic acid in a more pure state.
• Clavulanic acid (Z)-(2R,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid) is a ⁇ -lactamase inhibitor which is used commercially as a component of pharmaceutical formulations, usually in the form of its pharmaceutically acceptable salts, particularly potassium clavulanate.
• Clavulanic acid is produced commercially by culture of the microorganism Streptomyces clavuligerus , for example as described in GB 1508977.
• Clavulanic acid may be extracted from the culture medium in various ways. Normally the cells of the S. clavuligerus are first removed from the culture medium by such methods as filtration or centrifugation before such extraction procedures are commenced. The clavulanic acid may be extracted from this clarified culture medium by solvent extraction from cold clarified culture medium adjusted to an acid pH. Whole broth extraction is also feasible. In the solvent extraction process the clavulanic acid is extracted into an organic solvent. After separation of the phases clavulanic acid is found in solution in the organic phase.
• the clavulanic acid may be back extracted from the organic phase into a new aqueous phase by making use of the greater water solubility of salts of clavulanic acid with organic amines, and isolating such an amine salt from the aqueous phase.
• the amine salt is formed as an intermediate in the process of converting crude clavulanic acid into a pharmaceutically acceptable salt.
• Such a process is described in for example EP-A-0 026 044, in which a solution of impure clavulanic acid in an organic solvent is contacted with t-butylamine to form the t-butylamine salt of clavulanic acid, which is then isolated.
• WO-A-94/22873 discloses use of various tertiary, tertiary diamines such as N,N,N′,N′-tetramethyl-1,2-diaminoethane, N,N,N′,N′-tetramethyl-1,6-diaminohexane, 1,2-dipiperidinoethane and dipiperidinomethane.
• WO-A-96/20199 discloses use of diaminoethers such as bis (2-dimethylaminoethyl) ether.
• GB-A-2298201 discloses use of various benzhydrylamines.
• WO-A-96/33197 discloses use of further amines including symmetrical N,N′-alkylethylene diamines, such as N,N′-diisopropyl-ethylenediamine, N,N′-diethylene diamine, N,N′-dibenzylethylene diamine and N,N,N′,N′-tetramethylene diamine.
• WO-A-98/21212 discloses a process in which the amines N,N,N′,N′-tetramethylethylenediamine, 1,3-bis(di-methylamino)-2-propanol, benzhydrylamine and bis (2-(dimethylamino) ethyl) ether are used.
• WO-A-98/23622 discloses use of diisopropyl-ethylen-diamine.
• the intermediate amine salt may be converted into a pharmaceutically useful salt of clavulanic acid, particularly an alkali metal salt especially potassium clavulanate, generally by reaction of the intermediate amine salt with a salt precursor compound such as potassium 2-ethylhexanoate.
• a salt precursor compound such as potassium 2-ethylhexanoate.
• clavulanic acid is prepared also produces side product impurities.
• impurities have been identified as peaks in the HPLC trace of crude clavulanic acid, intermediate amine salts and pharmaceutically acceptable salts of clavulanic acid as prepared by conventional processes, but few have been chemically identified.
• One such impurity has recently been identified by the present inventors as N-succinyl tyrosine.
• impurities may be removed from the above-mentioned intermediate amine salt, during the step of conversion of the intermediate amine salt to the pharmaceutically acceptable salt, or from the final salt product.
• the process may be a purification process in which N-succinyl tyrosine is removed from a salt of clavulanic acid contaminated with it.
• the invention provides a purification process in which a salt of clavulanic acid, contaminated with or believed to be contaminated with N-succinyl tyrosine, is subjected to conditions which are selected to remove N-succinyl tyrosine.
• Such conditions may be chemical conditions, e.g. treatment with one or more suitable reagent.
• the salt of clavulanic acid, contaminated or believed to be contaminated with N-succinyl tyrosine may be subjected to such conditions by exposure to a liquid medium, e.g. an organic solvent or organic solvent-water mixture, containing such a reagent.
• Such a process may involve washing of the salt of clavulanic acid in a solid state with such a liquid medium, or crystallisation of the salt of clavulanic acid from such a liquid medium.
• the salt of clavulanic acid contaminated or believed to be contaminated with N-succinyl tyrosine, may be exposed to a suitable reagent in solid form.
• the purification process may be a process in which a salt of clavulanic acid, contaminated or believed to be contaminated with N-succinyl tyrosine, is suspended or dissolved in a liquid medium, e.g. an organic solvent or organic solvent-water mixture, and is exposed to a material which is selected to absorb N-succinyl tyrosine and thereby removes N-succinyl tyrosine from the salt.
• a liquid medium e.g. an organic solvent or organic solvent-water mixture
• the process may be a preparative process in which the salt of clavulanic acid is prepared under conditions selected to minimise the formation of N-succinyl tyrosine and/or its retention in the product salt of clavulanic acid.
• the salt of clavulanic acid may be prepared in a liquid medium, e.g. an organic solvent, an aqueous medium, or a mixture of an organic solvent, containing reagents which remove N-succinyl tyrosine, or subjected to chemical or physical conditions which remove N-succinyl tyrosine.
• the salt of clavulanic acid purified or prepared in the above processes may be an amine salt of clavulanic acid, e.g. with any of the amines referred to above, especially tertiary butylamine, and this amine salt may be subsequently be converted into a final product pharmaceutically acceptable salt of clavulanic acid, such as an alkali metal salt, e.g. potassium clavulanate.
• the salt may be a metal salt of clavulanic acid, for example an alkali metal salt of clavulanic acid, particularly potassium clavulanate.
• a process comprising exposure of a salt of clavulanic acid to a liquid medium at a pH of less than 6.5, preferably 6.0 or less, more preferably pH 5.5 or less, more preferably pH 5.0 or less, more preferably being above pH 3.5, e.g. pH 3.5-5.5, typically ca. pH 4.5.
• pH as used herein includes the conventional usage of the term pH as the logarithm of the reciprocal of the hydrogen ion concentration.
• pH as used herein includes the observed pH, i.e. the pH as measured by exposing the medium to a conventional pH meter of known type, suitably calibrated by known methods. Normally the media used in the process of this invention will contain some water.
• Treatment of the salt in this way in the process of the invention can reduce the level of one or more impurities, particularly of N-succinyl tyrosine, in the salt, or in further salts of clavulanic acid, e.g. a pharmaceutically acceptable salt, prepared from the salt.
• the salt may be washed with the medium, i.e. a wash medium, at a pH of less than 6.5, preferably pH 5.5 or less.
• the salt may be an amine salt of clavulanic acid, e.g. with any of the amines referred to above, especially tertiary butylamine, and this amine salt may be washed with the wash medium, and then optionally the amine salt may subsequently be converted into a final product pharmaceutically acceptable salt of clavulanic acid, such as an alkali metal salt, e.g. potassium clavulanate.
• the salt which is washed may be a metal salt of clavulanic acid, for example an alkali metal salt of clavulanic acid, particularly potassium clavulanate.
• the wash medium may be an aqueous wash medium at such a pH, e.g. acidified water or preferably a mixture of water and a water-miscible organic solvent such as a C 1-7 alkyl alcohol, typically containing 0.5-20% v:v water, at such a pH.
• aqueous wash medium e.g. water or such a mixture of water and a water-miscible organic solvent may be acidified with a mineral acid, such as sulphuric, hydrochloric or nitric acid, or an organic e.g. carboxylic acid such as a C 1-7 alkanoic acid such as acetic acid.
• This first form of the process may therefore be a process in which a starting salt of clavulanic acid is provided containing one or more impurity such as N-succinyl tyrosine, and the salt is washed with the wash medium, to thereby produce a product salt of clavulanic acid in which the level of the one or more impurity is lower.
• impurity such as N-succinyl tyrosine
• This first form of the process may therefore be a process in which the one or more impurity such as N-succinyl tryosine is removed from a starting salt of clavulanic acid, by washing of the starting salt of clavulanic acid with the wash medium.
• the one or more impurity such as N-succinyl tryosine
• the salt may be recrystallised from the medium at pH of less than 6.5.
• an amine salt may be recrystallised from such a recrystallisation medium, then may subsequently be converted into a final product pharmaceutically acceptable salt of clavulanic acid, such as an alkali metal salt, e.g. potassium clavulanate by known methods such as those referred to above, for example reaction with potassium 2-ethyl hexanoate.
• the salt e.g. an amine salt may be dissolved in an aqueous medium, e.g. acidified water or a mixture of water and a water-miscible organic solvent such as a C 1-7 alkyl alcohol.
• an aqueous medium e.g. acidified water or a mixture of water and a water-miscible organic solvent such as a C 1-7 alkyl alcohol.
• the solution concentration is high, e.g. e.g. 10-40% or more, but there appears to be no theoretical upper limit.
• the aqueous medium may initially be at the pH less than 6.5, or the pH may be adjusted when the aqueous solution has been made up, e.g.
• the aqueous solution may then be acidified with an acid, suitably a mineral acid, such as sulphuric, hydrochloric or nitric acid, or an organic acid e.g. carboxylic acid such as a C 1-7 alkanoic acid such as acetic acid.
• an acid suitably a mineral acid, such as sulphuric, hydrochloric or nitric acid, or an organic acid e.g. carboxylic acid such as a C 1-7 alkanoic acid such as acetic acid.
• a preferred pH is ca. 5.5 or lower.
• the salt e.g. an amine salt
• the salt may then be isolated from the aqueous solution. This may be achieved for example by crystallisation by admixing the solution, e.g. an aqueous solution, with a precipitating solvent, such as a water miscible ketone.
• a precipitating solvent such as a water miscible ketone.
• Suitable ketones include aliphatic ketones, for example a di-C 1-7 alkyl ketone, acetone being preferred.
• Solvates of amine clavulanate salts with such ketones are known and an amine salt may precipitate as a ketone solvate.
• the solution may be diluted with an excess, e.g. a 5-50 times excess of the precipitating solvent e.g. of a ketone. Cooling of the diluted solution can help to improve the yield of the precipitated of crystals of the amine salt, e.g. as a solvate, which may be isolated.
• This second form of the process may therefore be a process in which a starting salt of clavulanic acid is provided containing one or more impurity such as N-succinyl tyrosine, and the salt is recrystallised in the recrystallisation medium, to thereby produce a product salt of clavulanic acid in which the level of the one or more impurity is lower.
• impurity such as N-succinyl tyrosine
• This second form of the process may therefore be a process in which the one or more impurity is removed from a starting salt of clavulanic acid, by recrystallisation of the starting salt of clavulanic acid from the recrystallisation medium.
• a third form of the process may be a preparative process in which the salt of clavulanic acid is prepared in a liquid medium at the pH of less than 6.5.
• this third form of the process may comprise a process in which an amine salt of clavulanic salt is prepared by reacting clavulanic acid with an amine in a liquid medium at a pH of less than 6.5.
• This third form of the process can be used to prepare amine salts of clavulanic acid containing a lower level of impurities such as N-succinyl tyrosine than occur in amine salts of clavulanic acid prepared by alternative or prior art methods.
• the reaction is performed in a two phase system, being an organic solvent phase containing the clavulanic acid, and an aqueous phase into which the amine salt is extracted and which is at the pH of 6.5 or lower.
• the aqueous phase may comprise an aqueous solution or suspension of the amine, especially an aqueous solution or suspension of tertiary butylamine.
• the organic solvent phase is preferably substantially imiscible with water, that is, although some mixing of the solvent with water may occur, over most of the phase diagram two phases are formed.
• a two phase system comprising an organic solvent phase containing dissolved clavulanic acid, and a separate aqueous phase, and the organic amine may be introduced into this two phase system, e.g. injected into the aqueous phase, with suitable mixing conditions e.g. agitation or turbulence, so that the amine salt is extracted into the aqueous phase as it is formed.
• the organic phase may have a concentration of 5-100 g/L, for example 10-40 g/L in clavulanic acid, e.g. ca. 30 g/L.
• Suitable solvents for the organic phase include substantially water-immiscible C 1-7 alkyl-C 1-7 alkanoate esters such as ethyl acetate and tertiary butyl acetate, and di-C 1-7 alkyl ketones such as methylisobutyl ketone.
• a temperature of ca. 0-5° C. is preferred for this reaction.
• the organic solvent phase may be the product of an extraction by the organic solvent of an optionally pre-purified, e.g. filtered and carbon treated, fermentation broth in which clavulanic acid has been formed.
• the aqueous phase can be provided by back-extraction from the organic solvent phase by a circulating extraction loop so that a high concentration of the amine salt can be built up in the aqueous phase.
• the aqueous phase may be concentrated to a high concentration, e.g. 25 wt % or more e.g. by circulation of the aqueous extraction loop for a suitable time.
• the amine salt may then be isolated from the aqueous phase. This may be achieved for example by crystallisation by admixing the aqueous solution with a precipitating solvent, such as a water miscible ketone as described above, and this crystallisation can be performed in a manner analogous to the recrystallisation process as described above.
• a precipitating solvent such as a water miscible ketone as described above
• a fourth form of the process of the invention may be a preparative process in which a metal salt of clavulanic acid is formed as a product by a reaction between an amine salt of clavulanic acid and a metal salt precursor compound, in a liquid medium at the pH of less than 6.5.
• This fourth form of the process can be used to prepare metal salts of clavulanic acid containing a lower level of impurities such as N-succinyl tyrosine than occur in metal salts of clavulanic acid prepared by alternative or prior art methods.
• Preferred product metal salts of clavulanic acid which may be prepared in this fourth form of the process are salts of alkali metals and alkaline earth metals, particularly potassium clavulanate.
• This fourth form of the process of the invention appears to be suitable for use with all metal salt precursor compounds which can be converted into a pharmaceutically acceptable salt of clavulanic acid by reaction with an amine salt of clavulanic acid.
• suitable metal salt precursor compounds include salts of alkali metal cations and alkaline earth metal cations with counter anions which include basic anions, such as hydrogen carbonate, carbonate or hydrogen phosphate, and in particular anions of weak organic carboxylic acids, such as alkanoic acids of formula R—CO 2 H where R is C 1-20 alkyl, for example C 1-8 alkyl, e.g.
• salts of acetic, propionic and ethyl hexanoic acid such as 2-ethyl hexanoic acid.
• precursor compounds in these general classes include sodium or potassium hydrogen carbonate, potassium hydrogen phosphate and calcium carbonate.
• a preferred metal salt precursor compound for potassium clavulanate is potassium 2-ethylhexanoate.
• the reaction of this fourth form of the process of this invention is preferably performed with the amine salt in solution or suspension in a mixture of a water-miscible organic solvent and water, for example a C 1-8 alkyl alcohol or a mixture of such an alcohol with water, e.g. an isopropanol/water mixture.
• a solvent:water mixture containing 1-10% v:v water, e.g. ca. 1-5% v:v water.
• the amine salt may be dissolved in such a solvent which may be either at the pH of 6.0 or less, or which may be adjusted to the pH by addition of a suitable acid, e.g.
• the amine salt may suitably be present in a solution concentration 0.1-1.0M, e.g. ca. 0.5 M in clavulanate moiety.
• a preferred pH is 5.5 or below, e.g. pH 5.5-5.0.
• the metal salt precursor is preferably added to a solution of the amine salt.
• the precursor may be added as a solution, e.g. in an alcohol, e.g. isopropanol solution.
• a suitable solution concentration for this precursor compound solution is 0.5-3.5M, e.g. ca. 2M.
• Slow addition of the precursor solution is preferred, preferably with stirring and preferably being chilled after the addition a temperature below ambient e.g. 0-5° C.
• the metal salt of clavulanic acid product may be formed as a precipitate from solution. Precipitation of the product metal salt of clavulanic acid from solution may be encouraged by mixing the solution with a precipitating solvent, e.g. isopropanol, as described above.
• a precipitating solvent e.g. isopropanol, as described above.
• the solid product can be isolated from the reaction medium by for example filtration and washing of the product.
• the pH of the medium defined above can result in reduction of the quantity of one or more impurities such as N-succinyl tyrosine in the product relative to analogous processes at higher pH.
• These processes of the invention may comprise a part of an overall process for preparation of potassium clavulanate from crude clavulanic acid e.g. as formed in a fermentation broth, e.g. in which an amine salt is used as an intermediate.
• This overall process may involve the steps of (i) fermentation of a microorganism which produces an aqueous broth containing clavulanic acid, (ii) extraction of the clavulanic acid into an organic solvent, (iii) conversion of the clavulanic acid into an amine salt of clavulanic acid, (iv) exposure of the amine salt to a pH of 6.0 or lower, particularly 5.5 or lower, (v) conversion of the amine salt to potassium clavulanate.
• the washing and/or recrystallisation processes of the invention may for example be applied to the salts of clavulanic acid prepared as products of either or both of steps (iii) and/or (v).
• the preparative processes of the invention may for example be applied to either or both of preparation steps (iii) and/or (v), as described above.
• a preferred salt is potassium clavulanate.
• a preferred amine salt is the tertiary butylamine salt of clavulanic acid.
• This can be made, in a known (see for example EP-A-0 026 044, the content of which is included herein by reference) reaction, by reaction of tertiary butylamine with clavulanic acid, and easily isolated as an acetone solvate.
• Both the tertiary butylamine salt and its acetone solvate can readily be converted into pharmaceutically acceptable salts of clavulanic acid, e.g. potassium clavulanate, e.g. as disclosed in EP 0026044A.
• amines examples include for example amine poly-, e.g. di-, clavulanate salts if the amine has more than one amino-moiety.
• suitable amine salts include those referred to in the publications mentioned above, e.g.
• tertiary octylamine diethylamine, tri-(lower alkyl) amines, dimethylaniline, NN′-diisopropyl-ethylenediamine, tertiary, tertiary diamines such as N,N,N′,N′-tetramethyl-1,2-diaminoethane, N,N,N′,N′-tetramethyl-1,6-diaminohexane, 1,2-dipiperidinoethane and dipiperidinomethane, diaminoethers such as bis (2-dimethylaminoethyl) ether, benzhydrylamines, N,N′-alkylethylene diamines, such as N,N′-diisopropylethylene diamine, N,N′-diethylene diamine, N,N′-dibenzylethylene diamine, N,N,N′,N′-tetramethylene diamine, N,N,N
• the present invention further provides a product amine salt of clavulanic acid being a product of any of the above-described process, particularly tertiarybutylamine clavulanate.
• the present invention further provides a product pharmaceutically acceptable metal salt of clavulanic acid being a product of any of the above-described process, particularly potassium clavulanate.
• Examples 1, 2 and 3 are expressed in terms of the reduction of the total quantity of impurities in the product salt of clavulanic acid, and Examples 4, 5 and 6 are expressed in terms of reduction of the specific impurity N-succinyl tyrosine.
• t-BA tertiary-butylamine
• clavulanic acid aqueous concentrate (ca. 20-40 g/L), from filtered concentrated fermentation broth was solvent extracted at pH 1.5 into methyl isobutyl ketone (“MIBK”).
• MIBK methyl isobutyl ketone
• the clavulanic acid rich MIBK was treated with carbon (17 L) and back extracted into water which was adjusted to pH 4.5 by controlled injection of a 50% MIBK solution of t-BA.
• t-BA By controlling the t-BA addition rate the pH of the aqueous phase could be set, and pH 4.5 and pH 5.4 were used in separate experiments.
• a 100 ml aliquot was crystallised by addition of 35 volumes of acetone and the precipitated product isolated as in Example 1 above.
• the subsequent crystallised amine was converted to potassium salt and analysed for total impurity levels. This was then repeated with an aqueous phase pH of 5.4. By using the pH 4.5 the level of total impurities in the potassium clavulanate was reduced by 50% relative to the level at a pH of 5.4.
• Example 3 The experiments described in Example 3 above were repeated using other acids than acetic acid to achieve the specified pH, for example hydrochloric acid was used with similar results.
• t-BA tertiary-butylamine
• clavulanic acid aqueous concentrate (ca. 2040 g/L), from filtered concentrated fermentation broth was solvent extracted at pH 1.5 into methyl isobutyl ketone (“MIBK”).
• MIBK methyl isobutyl ketone
• the clavulanic acid rich MIBK was treated with carbon (17 L) and back extracted into water which was adjusted to pH 4.5 by controlled injection of a 50% MIBK solution of t-BA.
• t-BA By controlling the t-BA addition rate the pH of the aqueous phase could be set, and pH 4.5 and pH 5.4 were used in separate experiments.
• a 100 ml aliquot was crystallised by addition of 35 volumes of acetone and the precipitated product isolated as in Example 1 above.
• the subsequent crystallised amine was converted to potassium salt and analysed for N-succinyl tyrosine levels. This was then repeated with an aqueous phase pH of 5.4. By using the pH 4.5 the level of N-succinyl tyrosine impurity in the potassium clavulanate was reduced 26-fold relative to the level at a pH of 5.4.
• Example 3 The experiments described in Example 3 above were repeated using other acids than acetic acid to achieve the specified pH, for example hydrochloric acid was used with similar results.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Cephalosporin Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Pyrane Compounds (AREA)

Applications Claiming Priority (5)

Publications (2)

Family

ID=26244256

Family Applications (1)

Country Status (24)

Cited By (1)

Families Citing this family (6)

Citations (30)

Family Cites Families (1)

• 2001
  • 2001-05-09 CA CA2408853A patent/CA2408853C/en not_active Expired - Lifetime
  • 2001-05-09 AT AT01925753T patent/ATE273982T1/de active
  • 2001-05-09 ES ES01925753T patent/ES2225524T5/es not_active Expired - Lifetime
  • 2001-05-09 CZ CZ2002-3723A patent/CZ304775B6/cs not_active IP Right Cessation
  • 2001-05-09 NZ NZ522414A patent/NZ522414A/en not_active IP Right Cessation
  • 2001-05-09 EP EP01925753A patent/EP1284978B2/en not_active Expired - Lifetime
  • 2001-05-09 JP JP2001584285A patent/JP4954421B2/ja not_active Expired - Lifetime
  • 2001-05-09 CN CNB018094236A patent/CN1222528C/zh not_active Expired - Lifetime
  • 2001-05-09 AU AU52432/01A patent/AU776184B2/en not_active Expired
  • 2001-05-09 BR BRPI0110774A patent/BRPI0110774B8/pt not_active IP Right Cessation
  • 2001-05-09 DE DE60105016T patent/DE60105016T3/de not_active Expired - Lifetime
  • 2001-05-09 DK DK01925753T patent/DK1284978T4/da active
  • 2001-05-09 PL PL358368A patent/PL206316B1/pl unknown
  • 2001-05-09 WO PCT/GB2001/002025 patent/WO2001087891A1/en active Application Filing
  • 2001-05-09 KR KR1020027015169A patent/KR100827898B1/ko active IP Right Grant
  • 2001-05-09 PT PT01925753T patent/PT1284978E/pt unknown
  • 2001-05-09 HU HU0300869A patent/HU228593B1/hu unknown
  • 2001-05-09 US US10/275,852 patent/US7767823B2/en active Active
  • 2001-05-09 MX MXPA02011192A patent/MXPA02011192A/es active IP Right Grant
  • 2001-05-09 IL IL15264301A patent/IL152643A0/xx unknown
  • 2001-05-09 SI SI200130207T patent/SI1284978T2/sl unknown
• 2002
  • 2002-11-04 IL IL152643A patent/IL152643A/en active IP Right Grant
  • 2002-11-11 ZA ZA2002/09141A patent/ZA200209141B/en unknown
  • 2002-11-12 NO NO20025422A patent/NO328528B1/no not_active IP Right Cessation
• 2003
  • 2003-08-21 HK HK03106008A patent/HK1055111A1/xx not_active IP Right Cessation

Patent Citations (31)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events